The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease

¹Department of Radiation Oncology, UCLA, Los Angeles, California;
²Department of Urology, UCLA, Los Angeles, California;
³Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia;
⁴Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia;
⁵Roentgeninstitut Duesseldorf, Duesseldorf, Germany;
⁶Department of Radiation Oncology and Molecular Radiation Sciences, School of Medicine, Johns Hopkins University, Baltimore, Maryland;
⁷Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland; and
⁸Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California

For correspondence or reprints, contact Amar U. Kishan (aukishan{at}mednet.ucla.edu).

Statistics from Altmetric.com